Specialized Baclofen Suspensions for Niche Environments

Publication ID: 24-11857524_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Baclofen Suspensions for Niche Environments,” Published Technical Disclosure No. 24-11857524_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857524_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,524.

Summary of the Inventive Concept

The present inventive concept relates to specialized oral suspensions of baclofen adapted for specific, narrow market or unique operational environments, such as disaster relief, high-security needs, or extreme weather conditions.

Background and Problem Solved

The original patent provides stable oral suspensions of baclofen for general use. However, there is a need for tailored solutions that cater to specific, high-stakes situations where the standard suspensions may not be effective or reliable. The present inventive concept addresses this limitation by developing suspensions that are optimized for particular environments or scenarios.

Detailed Description of the Inventive Concept

The inventive concept encompasses a range of specialized oral suspensions of baclofen, each designed to meet the unique demands of a specific niche environment. For instance, the suspension for disaster relief is packaged in a waterproof container to ensure stability during transportation and storage in extreme weather conditions. The suspension for high-security environments is prepared in a secure facility and stored in a tamper-evident container to prevent unauthorized access or tampering. Similarly, the suspension for remote patient monitoring is packaged with a built-in sensor to monitor the suspension's pH and temperature during storage and transportation.

Novelty and Inventive Step

The new claims introduce novel features that are not obvious from the original patent, such as the use of waterproof containers, secure facilities, and tamper-evident containers. These innovations provide a significant advantage in terms of stability, security, and reliability in specific niche environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include suspensions optimized for other niche environments, such as search and rescue operations, military deployments, or space exploration. Variations may also include different packaging materials, container designs, or sensor technologies to further enhance the suspensions' performance in specific scenarios.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including pharmaceuticals, disaster relief, healthcare, and security. The target market includes government agencies, non-profit organizations, and private companies operating in high-stakes environments where reliable and effective medication is critical.

Field of Art

Pharmaceutical formulation and drug delivery systems, specifically focusing on liquid oral suspensions of muscle relaxant medications with emphasis on stability, packaging, and specialized medical delivery

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in drug suspension design, packaging technologies, and medical product development, holding advanced degrees in pharmaceutical sciences with practical experience in developing specialized medical delivery systems

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about stable baclofen suspensions. The fundamental pharmaceutical composition remains consistent, with the innovations primarily addressing packaging, delivery context, and environmental adaptations. These modifications represent standard design choices within pharmaceutical product development that would be obvious to a skilled practitioner seeking to optimize drug delivery for specific use cases.

Obvious Combinations & Variations

Source Patent Element
Stable liquid suspension of baclofen at 2 mg/mL concentration with pharmaceutically acceptable excipients
PTD Variation
Waterproof container for disaster relief suspension
Obviousness Reasoning
Packaging optimization is a routine design choice for pharmaceutical products, with predictable techniques for ensuring stability and protecting medication integrity in challenging environments
Source Patent Element
Suspension with pH range between 4-8 and various stabilizing excipients
PTD Variation
Container with built-in pH and temperature sensor for monitoring
Obviousness Reasoning
Integration of monitoring technologies represents a predictable technological advancement in pharmaceutical packaging, leveraging known sensor and quality control techniques
Source Patent Element
Aqueous suspension with stabilizing agents
PTD Variation
Sterilization using gamma radiation for immunocompromised patients
Obviousness Reasoning
Sterilization techniques are well-established in pharmaceutical manufacturing, representing a known method for creating specialized medical formulations for specific patient populations
Source Patent Element
Suspension with antifoaming and suspending agents
PTD Variation
Tamper-evident container for high-security environments
Obviousness Reasoning
Container security modifications are standard design variations in pharmaceutical packaging, representing a predictable solution for specialized distribution contexts
Source Patent Element
Stable oral suspension with pharmaceutically acceptable excipients
PTD Variation
Emergency medical response kit with dosing chart and syringe
Obviousness Reasoning
Supplementary packaging and administration tools are routine extensions of pharmaceutical product design, representing standard approaches to improving medication usability
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857524 and the present published technical disclosure, a person of ordinary skill in the art would find the claimed variations obvious, as they represent predictable modifications to a known stable baclofen suspension. The disclosed innovations constitute routine pharmaceutical design choices that would be apparent to a skilled practitioner seeking to adapt the base formulation for specialized medical delivery contexts.

Original Patent Information

Patent NumberUS 11,857,524
TitleStable oral suspensions of baclofen
Assignee(s)ANI Pharmaceuticals, Inc.